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CASE REPORT

Small-Cell Lung Cancer Presenting with Personality Change
Brian F. King MD, Heidi Horstman MD, Katherine Rizzolo MD
Department of Medicine, Maine Medical Center, Portland, ME
Introduction:

Paraneoplastic limbic encephalitis is a syndrome characterized by autoimmune inflammation of the
limbic system in the setting of underlying malignancy.1 The syndrome presents with acute to subacute
neuropsychiatric clinical findings, often before the cancer diagnosis.2,3

Clinical findings:

A 57-year-old woman with a 30 pack–year smoking history presented to an acute care hospital after
multiple generalized tonic-clonic seizures. Her family reported that she periodically showed odd
behavior, including confusion, disinhibition, and paranoia. All of these symptoms preceded her first
seizure by 2 weeks.

Diagnoses,
Interventions,
and Outcomes:

Brain magnetic resonance imaging revealed T2-weighted-fluid-attenuated inversion recovery (T2/
FLAIR) signal hyperintensity of the right amygdala and hippocampus, with sparing of the right insular
cortex and cingulate gyrus. Electroencephalogram showed frequent right-temporal simple partial
seizures. Her cerebrospinal fluid indicated mild pleocytosis and was positive for γ-aminobutyric
acid-B receptor (GABA-BR) antibodies with a titer of 1:32 (reference range <1:2). Levetiracetam,
fosphenytoin, lacosamide, and benzodiazepines were required to control seizure activity. Computed
tomography of her chest, abdomen, and pelvis revealed a 4-millimeter subpleural parenchymal nodule
in the left hilum. Positron emission tomographic-computed tomography showed hypermetabolic
density in the left hilum and a left-sided enlarged lymph node in the mediastinum. Bronchoscopy with
transbronchial needle biopsy confirmed small-cell lung cancer. After remission, the patient remained
free of recurrent seizures.

Conclusions:

This case illustrates the importance of early diagnosis and treatment of paraneoplastic limbic
encephalitis. Because paraneoplastic limbic encephalitis is often associated with undiagnosed
malignancy, recognizing the condition early can lead to timely initiation of tumor treatment.
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CASE PRESENTATION
A 57-year-old woman with a 30 pack–year smoking
history presented with 2 generalized tonic-clonic
seizures in the prior 3 days. Her family reported that
during the previous 2 weeks, the patient periodically
showed odd behavior, including confusion,
disinhibition, and paranoia.
On admission to the hospital the patient’s
hematology and chemistry results were within
normal ranges. Her neurologic exam revealed
fluctuating orientation and short-term memory
deficits, and her psychiatric exam showed pressured
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speech, hyper-emotionality, and inattention. Her
cerebrospinal fluid indicated 16 leukocytes/mm3
with 90% lymphocytic predominance and was
positive for γ-aminobutyric acid-B receptor (GABABR) antibodies with a titer of 1:32 (reference range
<1:2). Her brain magnetic resonance imaging (MRI)
showed T2-weighted-fluid-attenuated inversion
recovery (T2/FLAIR) signal hyperintensity of the
right amygdala and hippocampus, with sparing
of the right insular cortex and cingulate gyrus.
Electroencephalogram (EEG) revealed frequent
right-temporal simple partial seizures. These
findings were consistent with paraneoplastic limbic
encephalitis.
During her hospitalization, the patient required
levetiracetam, fosphenytoin, and lacosamide to
manage refractory right-temporal lobe seizures.
1

Journal of Maine Medical Center, Vol. 2 [2020], Iss. 1, Art. 9

She was given 1,000 mg methylprednisolone for
3 days. After her symptoms improved, she was
evaluated for underlying malignancy. Computed
tomography (CT) of her chest, abdomen, and pelvis
revealed a 4-mm subpleural parenchymal nodule
in the left hilum and two adrenal nodules in the left
adrenal gland. To help determine the biopsy site,
she underwent a positron emission tomographic
(PET)-CT, which revealed hypermetabolic density
in the left hilum and a left-sided enlarged lymph
node in the mediastinum. Bronchoscopy with
transbronchial needle biopsy confirmed smallcell lung cancer. One year after remission of her
cancer, she remained without recurrent seizures on
a regimen of antiepileptic drugs for paraneoplastic
epilepsy.

DISCUSSION
Paraneoplastic limbic encephalitis is a rare disease
characterized by inflammation of the limbic system.3
It typically manifests as neuropsychiatric clinical
findings and is often associated with malignancy.1
Its clinical presentation includes subacute memory
deficits, mood changes, hallucinations, paranoia,
psychosis, sleep disturbances, or seizures.4 Due
to the wide spectrum of disease presentation and
sometimes challenging diagnosis, the time to
treating the underlying malignancy is often delayed
for a median of 4 months.2 This highlights the
importance of promptly recognizing the combination
of symptoms associated with paraneoplastic limbic
encephalitis.
Classic paraneoplastic encephalitis is the result
of antibodies against intracellular neuronal
proteins,1,5 such as Hu, collapsin responsemediator protein-5 (CRMP5), Ri, Yo, or Ma2, as
well as their associated paraneoplastic syndromes.
These syndromes are often associated with
malignancy and older age, and they may have a
poorer response to immunotherapy. The antibodies
directed against intracellular proteins elicit cytotoxic
T–cell inflammation and often permanent neuronal
damage.4 In contrast to classic paraneoplastic
encephalitis, autoimmune encephalitis includes
syndromes characterized by antibodies against
neuronal or synaptic cell–surface proteins,4 such
as the N-methyl-D-aspartate (NMDA) receptor,
leucine-rich glioma-inactivated 1 (LGI1), α-amino3-hydroxy-5-methyl-4-isoxazolepropionic
acid
receptor (AMPAR), metabotropic glutamate receptor
5 (mGluR5), or contactin-associated protein-like 2
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(Caspr2), as well as their associated autoimmune
syndromes. These syndromes are less likely to be
associated with malignancy, are associated with
younger age, and often have a better response to
immunotherapy. Antibodies targeting extracellular
membrane domains of cell-surface antigens can
regulate the function or quantity of the target
protein, resulting in neuronal dysfunction, but not
neuronal destruction.
Notably, a third group of antibody-associated
encephalitis has emerged, shifting the classic
paradigm of paraneoplastic and autoimmune
encephalitis.10 This group includes mixed features
of each syndrome, as seen in this case of small-cell
lung cancer with associated antibodies to GABA-BR,
a cell surface receptor. Another prominent example
of cancer-associated autoimmune encephalitis is
NMDA-receptor encephalitis, which is sometimes
associated with ovarian teratoma. Several other
autoimmune
encephalitides
(e.g., AMPAR,
GABA-A, mGluR5) may be idiopathic or associated
with underlying malignancy. For example, a recent
review found that half of 20 patients with GABA-BR
limbic encephalitis had associated paraneoplastic
encephalitis and the other half had idiopathic
or autoimmune encephalitis.9 The underlying
malignancy was small-cell lung cancer, as seen
in this case. This case further underscores the
strong association of malignancy with both classic
paraneoplastic encephalitis and autoimmune
encephalitis, as well as the importance of pursuing
screening for underlying tumors.3
Paraneoplastic limbic encephalitis is diagnosed
based on cerebrospinal fluid pleocytosis, positive
antibodies, EEG with focal epileptiform activity,
and hyperattenuation on T2/FLAIR of the limbic
system with sparing of the insular cortex and
cingulate gyrus.7 The differential diagnosis often
includes acute disseminated encephalomyelitis,
neuromyelitis optica spectrum disorders, and
demyelinating syndromes. These diagnoses can
exist concurrently.4 Treatment is largely supportive
and involves modulating the immune system with
steroids or intravenous immunoglobulin, as well
as managing seizures with antiepileptic drugs.1,7
Ongoing evaluation for a diagnosis should not
impede empiric treatment, as delayed treatment
increases the risk of permanent sequelae. Definitive
treatment of paraneoplastic limbic encephalitis is
treatment of the underlying malignancy.1
2
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Figure 1. Brain MRI without contrast. Abnormal and asymmetric T2/FLAIR signal
hyperintensity in the right amygdala and the entire right hippocampal formation. MRI,
magnetic resonance imaging; T2/FLAIR, T2-weighted-fluid-attenuated inversion
recovery.

Figure 2. PET-CT of mid-lung. The scan revealed a nodular density measuring
approximately 10 x 9 cm at the left hilum, consistent with a borderline-enlarged left
hilar lymph node. PET-CT, positron emission tomographic computed tomography.
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